Chong Kun Dang Pharmaceutical Corp.

Robust Pipeline of 55+ Therapies Advancing Toward Potential Functional Cure for Chronic Hepatitis B

a month ago

• Over 50 pharmaceutical companies are actively developing 55+ pipeline therapies for chronic hepatitis B virus (HBV) infection, signaling a robust research landscape aimed at achieving functional cures beyond current suppressive treatments. • Promising candidates include Pradefovir (Ligand Pharmaceuticals) in Phase III and RG6346 (Dicerna/Roche) in Phase II, with the latter demonstrating over 99.9% reduction in circulating HBsAg in preclinical models. • GlaxoSmithKline and Vir Biotechnology are pioneering combination approaches, with GSK evaluating sequential therapy of ASO compound (GSK3228836) and CHB-TI (GSK3528869A) to potentially enhance efficacy over monotherapy in chronic HBV patients.

Androgenetic Alopecia Pipeline Shows Promise with Over 100 Therapies in Development

2 months ago

• DelveInsight's latest report reveals a robust pipeline for androgenetic alopecia with 80+ companies developing 100+ therapeutic candidates across various clinical stages. • Key emerging treatments include KX-826 from Kintor Pharma and Clascoterone from Cassiopea, which could significantly expand options beyond the current FDA-approved minoxidil and finasteride. • Recent clinical trial results from companies like Veradermics, Chong Kun Dang, and Pelage Pharmaceuticals demonstrate increasing R&D investment in addressing this common condition affecting up to 50% of both men and women.